These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 31214877)
1. Realgar transforming solution-induced differentiation of NB4 cell by the degradation of PML/RARα partially through the ubiquitin-proteasome pathway. Hai Y; Wang X; Song P; Li JY; Zhao LH; Xie F; Tan XM; Xie QJ; Yu L; Li Y; Wu ZR; Li HY Arch Pharm Res; 2019 Aug; 42(8):684-694. PubMed ID: 31214877 [TBL] [Abstract][Full Text] [Related]
2. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation. Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848 [TBL] [Abstract][Full Text] [Related]
4. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191 [TBL] [Abstract][Full Text] [Related]
5. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies. Giannì M; de Thé H Leukemia; 1999 May; 13(5):739-49. PubMed ID: 10374879 [TBL] [Abstract][Full Text] [Related]
6. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution. Wang X; Zhang X; Xu Z; Wang Z; Yue X; Li H Biol Pharm Bull; 2013; 36(4):641-8. PubMed ID: 23358330 [TBL] [Abstract][Full Text] [Related]
7. The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells. Jing Y; Xia L; Lu M; Waxman S Oncogene; 2003 Jun; 22(26):4083-91. PubMed ID: 12821942 [TBL] [Abstract][Full Text] [Related]
8. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688 [TBL] [Abstract][Full Text] [Related]
9. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181 [TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816 [TBL] [Abstract][Full Text] [Related]
11. PML-RARα stabilized by zinc in human acute promyelocytic leukemia NB4 cells. Zhu B; Wang JY; Zhou JJ; Zhou F; Cheng W; Liu YT; Wang J; Chen X; Chen DH; Luo L; Hua ZC J Inorg Biochem; 2017 Oct; 175():92-100. PubMed ID: 28743050 [TBL] [Abstract][Full Text] [Related]
12. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733 [TBL] [Abstract][Full Text] [Related]
13. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Fanelli M; Minucci S; Gelmetti V; Nervi C; Gambacorti-Passerini C; Pelicci PG Blood; 1999 Mar; 93(5):1477-81. PubMed ID: 10029573 [TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin-3-gallate promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells via PTEN. Yao S; Zhong L; Chen M; Zhao Y; Li L; Liu L; Xu T; Xiao C; Gan L; Shan Z; Liu B Int J Oncol; 2017 Sep; 51(3):899-906. PubMed ID: 28766684 [TBL] [Abstract][Full Text] [Related]
15. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. Müller S; Matunis MJ; Dejean A EMBO J; 1998 Jan; 17(1):61-70. PubMed ID: 9427741 [TBL] [Abstract][Full Text] [Related]
16. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Zhu J; Lallemand-Breitenbach V; de Thé H Oncogene; 2001 Oct; 20(49):7257-65. PubMed ID: 11704854 [TBL] [Abstract][Full Text] [Related]
17. Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia. Kitamura K; Kiyoi H; Yoshida H; Saito H; Ohno R; Naoe T Leukemia; 1997 Nov; 11(11):1950-6. PubMed ID: 9369431 [TBL] [Abstract][Full Text] [Related]
18. [Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells]. Ni J; Chen G; Zhu J; Zhong H; Tang W; Li X; Xiong S; Shen Z; Chen S; Wang Z; Chen L Zhonghua Xue Ye Xue Za Zhi; 1997 Jan; 18(1):32-4. PubMed ID: 15622748 [TBL] [Abstract][Full Text] [Related]
19. Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia. Yang XW; Wang P; Liu JQ; Zhang H; Xi WD; Jia XH; Wang KK Oncogene; 2014 May; 33(21):2700-8. PubMed ID: 23770850 [TBL] [Abstract][Full Text] [Related]
20. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. Li L; Wang J; Ye RD; Shi G; Jin H; Tang X; Yi J J Cell Physiol; 2008 Nov; 217(2):486-93. PubMed ID: 18636556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]